Fresh off its FY 2025 third quarter update, Editas Medicine (EDIT) posted revenue of US$7.5 million with a basic EPS loss of US$0.28. Trailing 12 month figures show revenue of US$46.4 million and a basic EPS loss of US$2.35. Over recent quarters the company has seen revenue move from US$30.6 million in Q4 2024 to US$4.7 million in Q1 2025, US$3.6 million in Q2 2025 and US$7.5 million in Q3 2025. Basic EPS losses were US$0.55, US$0.92, US$0.63 and US$0.28 across those same periods as investors weigh the appeal of forecast revenue growth against ongoing pressure on margins.

See our full analysis for Editas Medicine.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the dominant market narratives around Editas and where the data pushes back on those stories.

Losses Narrow To US$25.1 Million In Q3

• Net income loss in Q3 FY 2025 was US$25.1 million, compared with losses of US$53.2 million in Q2 and US$76.1 million in Q1, while trailing 12 month losses stood at US$199.8 million.
• What stands out for a more cautious, bearish view is that even with this quarterly improvement, trailing 12 month basic EPS is still a loss of US$2.35 and trailing net income loss is US$199.8 million. This lines up with forecasts that earnings could decline by about 7.4% per year over the next three years.
  • Critics point out that the company has remained loss making across all reported quarters, with quarterly net income losses ranging from US$25.1 million to US$76.1 million in FY 2025 data.
  • Bears also highlight that forecasts call for the business to stay unprofitable over the next three years, so the recent Q3 loss level is being viewed against that backdrop rather than as a signal of a clear shift in profitability.

Revenue Forecast At 20.2% Growth While Cash Runway Is Tight

• Revenue across the trailing 12 months is US$46.4 million and is forecast to grow at about 20.24% per year, while the company is flagged as having less than one year of cash runway and is expected to remain unprofitable over the next three years.
• Supporters of a more optimistic, bullish angle focus on the projected 20.24% revenue growth rate. That view sits alongside the fact that trailing 12 month net income is a loss of US$199.8 million and the business has under one year of cash runway.
  • Consensus narrative notes that revenue growth is the primary upside signal, but the forecast decline in earnings of around 7.4% per year over the next three years keeps profitability risk front and center.
  • What is most important for that bullish angle is how investors weigh the potential for higher top line against ongoing losses and the need to address the limited cash runway that has been identified.

To see how other investors are weighing that trade off between growth and cash risk, check out the range of views in Curious how numbers become stories that shape markets? Explore Community Narratives.

P/S Of 4.9x Sits Between Peers And Wider Biotech

• Editas is trading on a P/S ratio of 4.9x, compared with a peer average of 4x and a broader US biotechs industry average of 12x, against trailing 12 month revenue of US$46.4 million and a share price of US$2.32.
• For more cautious, bearish investors, that 4.9x P/S multiple is seen as requiring careful attention to the risk profile, since the company is unprofitable, has less than one year of cash runway and consensus forecasts call for earnings to decline by about 7.4% per year over the next three years.
  • Some point to the combination of a higher P/S than direct peers, shareholder dilution in the past year and continued losses of US$199.8 million over the trailing 12 months as reasons to be selective at this valuation level.
  • Others focus on the fact that the P/S ratio is still below the US biotechs industry average of 12x, so the mixed valuation position tends to sharpen the debate around how much risk investors are comfortable taking on given the earnings outlook.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Editas Medicine's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of bullish and bearish points feels finely balanced, consider reviewing the numbers yourself and pressure testing the story, starting with 1 key reward and 5 important warning signs.

Explore Alternatives

Editas Medicine still reports trailing 12 month net income losses of US$199.8 million, limited cash runway and forecasts pointing to ongoing unprofitability alongside earnings declines.

If that level of loss and cash strain feels uncomfortable, take a moment to look at 65 resilient stocks with low risk scores that aim to keep downside risk and financial stress in tighter check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.